Licoisoflavone B

Licoisoflavone B is an orally active flavonoid found in licorice. Licoisoflavone B alleviates psoriasis via SCD1-targeted lipid metabolism reprogramming and suppression of Th17/IL-17-mediated inflammation. Licoisoflavone B inhiibits superoxide anion generation and superoxide anion-induced lipid peroxidation. Licoisoflavone B binds tightly to Lassa virus nucleoprotein and can be used as a nucleoprotein antagonist of Lassa virus. Licoisoflavone B exhibits anti-mutagenic activity
against carcinogenic mutagen, by preventing DNA damage. Licoisoflavone B can be used for the research of psoriasis, Lassa fever, inflammation and cancer^[1][2][3][4]. In Vitro:Licoisoflavone B binds directly to purified SCD1 protein with a K_d of 7.1 μM^[1].
Licoisoflavone B (0-15 μM; 24 h) exhibits no cytotoxicity toward HaCaT keratinocytes at concentrations ≤12 μM^[1].
Licoisoflavone B (9 μM; 24 h) attenuates IL-17-induced SCD1 upregulation and lipid droplet accumulation in HaCaT keratinocytes^[1].
Licoisoflavone B (9 μM; 24 h) suppresses IL-17-driven hyperproliferation of HaCaT keratinocytes^[1].
Licoisoflavone B (100 μM; 10 min) inhibits superoxide anion-induced lipid peroxidation in a cell-free lecithin-based assay with an IC₅₀ of 2.7 μM, and exhibits a 92.5% inhibitory ratio at 100 μM^[2].
Licoisoflavone B (100 μM; 20 min) inhibits superoxide anion generation in a cell-free xanthine-xanthine oxidase assay with an IC₅₀ of 31.2 μM and exhibits a 58.3% inhibitory ratio at 100 μM^[2].
Licoisoflavone B binds tightly to Lassa virus nucleoprotein (PDB ID: 3MX5) with a binding affinity of -10.1 kcal/mol^[3]. In Vivo:Licoisoflavone B (40-160 mg/kg; p.o.; daily; 6 days) alleviates Imiquimod (HY-B0180)-induced psoriasis-like pathology in male C57BL/6 mice^[1].
Licoisoflavone B (40-160 mg/kg; p.o.; daily; 6 days) is well-tolerated in healthy male C57BL/6 mice at doses up to 160 mg/kg administered orally daily for 6 days, with no detected hepatic or renal toxicity^[1].